Reviewing Glaukos (NYSE:GKOS) and Biotricity (OTCMKTS:BTCY)

Glaukos (NYSE:GKOS – Get Rating) and Biotricity (OTCMKTS:BTCY – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Insider and Institutional Ownership

92.2% of Glaukos shares are held by institutional investors. Comparatively, 4.8% of Biotricity shares are held by institutional investors. 8.1% of Glaukos shares are held by insiders. Comparatively, 20.5% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Glaukos and Biotricity, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	0	4	5	0	2.56
Biotricity	0	1	1	0	2.50

Glaukos presently has a consensus price target of $56.67, suggesting a potential upside of 17.64%. Biotricity has a consensus price target of $4.00, suggesting a potential upside of 400.00%. Given Biotricity’s higher probable upside, analysts clearly believe Biotricity is more favorable than Glaukos.

Volatility and Risk

Glaukos has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Biotricity has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.

Profitability

This table compares Glaukos and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glaukos	-31.45%	-16.16%	-8.96%
Biotricity	-265.11%	-6,795.29%	-155.92%

Valuation & Earnings

This table compares Glaukos and Biotricity’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$294.01 million	7.82	-$49.59 million	($1.90)	-25.35
Biotricity	$7.70 million	5.39	-$29.13 million	($0.46)	-1.74

Biotricity has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Summary

Glaukos beats Biotricity on 8 of the 14 factors compared between the two stocks.

About Glaukos

(Get Rating)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

About Biotricity

(Get Rating)

Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It is also involved in delivering remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm’s FDA-approved Bioflux MCT technology is comprised of monitoring device and software components, which are made available to the market to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.